Janssen/Legend’s Cilta-Cel Responses Could Make Up For Second-To-Market Position
Mitigation Strategy Lessens Neurotoxicity Of CAR-T In Myeloma
Cilta-cel likely will be the second BCMA-targeting CAR-T therapy approved in the US for multiple myeloma, but appears to have an efficacy advantage over BMS/bluebird’s first-to-market Abecma.
You may also be interested in...
Janssen priced the one-time autologous treatment at $465,000, well above the $419,500 list price for Bristol’s first-to-market CAR-T, but expects broad commercial and Medicare coverage.
The partners reported initial data at ASH for their BCMA-targeting CAR-T therapy in second-line multiple myeloma that appear consistent with longer-term results and ahead of their main competitor, Bristol’s Abecma.
The company is winding down its autologous myeloma CAR-T program as competition in that market heats up and interest in off-the-shelf CAR-Ts grows.